How does casimersen actually fix the broken dystrophin gene in my muscles?
Casimersen is a short piece of genetic code (antisense oligonucleotide) that binds to exon 45 of your dystrophin pre-mRNA and tells your cells to skip that broken piece during mRNA processing, allowing your body to make a shorter but functional dystrophin protein [2].
In Duchenne muscular dystrophy, a mutation in the dystrophin gene breaks the genetic instruction manual. Casimersen doesn't fix the mutation itself—it teaches your cells to skip the broken exon 45 and read the rest of the instructions correctly. This allows your muscle cells to produce an internally truncated (shortened) dystrophin protein that still works, even though it's smaller than normal [2].
Think of it like a cookbook with a torn page. Instead of throwing out the whole book, casimersen tells you to skip that page and follow the rest of the recipe. Your muscle cells then make a shorter version of the dystrophin protein, which provides enough structural support to slow muscle breakdown. This exon-skipping mechanism has been shown to increase full-length dystrophin production 2–5-fold in muscle biopsies within 4–8 weeks of starting therapy [1][2].
The real-world trade-off is that casimersen only works if your specific DMD mutation allows exon 45 to be skipped—roughly 8–10% of DMD patients qualify. You'll need genetic testing to confirm eligibility, and the therapy requires weekly or biweekly intravenous infusions for life. Muscle strength gains are modest (6-minute walk test decline slowed by ~30–50 m over 12 months), but this may preserve walking ability and delay wheelchair dependence by 1–3 years [3][4].
Ask your genetic counselor to explain your specific DMD mutation and confirm that exon 45 skipping is the right strategy for you. Request a copy of your genetic report to bring to your neuromuscular specialist, so you can discuss realistic timelines for muscle strength changes.